Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Company Formed to Develop Spore-Based Next-Generation Vaccines

By BiotechDaily International staff writers
Posted on 06 Nov 2012
Scientists at Royal Holloway, University of London (London, UK), have developed a pioneering method of vaccination that served as the basis for receiving private seed investment used to form the new company, Holloway Immunology, to further develop the vaccine technology. The company is currently seeking additional investors to help fast track implementation of this new form of vaccine delivery.

Prof. Simon Cutting led the development using probiotic spores. He and his laboratory had been carrying out fundamental biology studies of Bacillus subtilis, which forms spores that can last millions of years before germinating under appropriate conditions. They later found that Bacillus spores can also act as effective vehicles to carry antigens and promote an immune response. "Rather than requiring needle delivery, vaccines based on Bacillus spores can be delivered via a nasal spray, or as an oral liquid or capsule. Alternatively, they can be administered via a small soluble film placed under the tongue [...]. As spores are exceptionally stable, vaccines based on Bacillus do not require cold-chain storage, alleviating a further issue with current vaccine approaches," explained Prof. Cutting. Besides eliminating pain associated with needles, oral vaccines are also safer to administer (especially in developing countries), inexpensive to produce, easier to store, and reduce concerns of adverse reactions.

Prof. Cutting and his team have carried out preclinical evaluation of Bacillus-based vaccines for a number of diseases including tuberculosis (TB), influenza, and tetanus. A Bacillus-based vaccine could boost the immunity provided by, or possibly even replace, existing vaccines against these diseases. They have also begun investigating the potential use of this technology against Clostridium difficile. “There is no vaccine against the disease, and although several approaches are currently undergoing clinical trials, none are expected to provide full protection," said Prof. Cutting. Also, unlike other current approaches, oral delivery can cause a more specific immune response in the gastrointestinal tract to more effectively eliminate C.difficile.

Holloway Immunology will initially concentrate development of the Bacillus spore based technology for three lead vaccines: against TB, influenza, and C. difficile.

Related Links:

Royal Holloway, University of London






comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A scheme for the generation of induced pluripotent stem cells (IPSC). (1) Isolate and culture donor cells. (2) Transfect stem cell-associated genes into the cells by viral vectors. Red cells indicate the cells expressing the exogenous genes. (3)  Harvest and culture the cells using mitotically inactivated feeder cells. (4) A small subset of the transfected cells forms iPSC cell colonies (Photo courtesy of Wikimedia Commons).

Innovative Technique Produces More Reliable Pluripotent Stem Cells

A recent paper described a more reliable way to induce the formation of pluripotent stem cells (iPSCs) from adult cells in a mouse model. Reliable high-quality iPSCs are needed for the development of... Read more

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.